Candel Therapeutics (NASDAQ:CADL) Shares Down 5.3%

Candel Therapeutics, Inc. (NASDAQ:CADLGet Rating) shares traded down 5.3% during trading on Wednesday . The company traded as low as $3.20 and last traded at $3.21. 6,148 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 33,482 shares. The stock had previously closed at $3.39.

Analyst Upgrades and Downgrades

Separately, Credit Suisse Group cut their price target on shares of Candel Therapeutics to $11.00 in a research report on Monday, August 15th.

Candel Therapeutics Price Performance

The company has a current ratio of 14.86, a quick ratio of 14.86 and a debt-to-equity ratio of 0.34. The company’s 50-day moving average is $3.41 and its two-hundred day moving average is $3.81.

Institutional Trading of Candel Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CADL. Empirical Asset Management LLC purchased a new stake in Candel Therapeutics in the 1st quarter valued at about $61,000. Kestra Advisory Services LLC acquired a new stake in shares of Candel Therapeutics in the first quarter worth $64,000. 683 Capital Management LLC purchased a new stake in Candel Therapeutics during the fourth quarter worth $320,000. BlackRock Inc. boosted its holdings in Candel Therapeutics by 15.5% during the first quarter. BlackRock Inc. now owns 132,322 shares of the company’s stock worth $674,000 after buying an additional 17,708 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of Candel Therapeutics in the second quarter worth about $2,408,000. 21.97% of the stock is currently owned by institutional investors.

Candel Therapeutics Company Profile

(Get Rating)

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.

Featured Stories

Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with's FREE daily email newsletter.